scm logo

SCM Life Science (SCM Life Science, CEO Lee Byung-gun), Korea's leading cell therapy company, was officially invited to the 39th JPMorgan Healthcare Conference, the world's largest pharmaceutical and bio event. SCM Life Science plans to speed up the technology transfer of its various cell therapy pipelines at the event. 

On the 21st, SCM Life Science announced that it will be invited to attend the JPMorgan Healthcare Conference, which will be held online from January 11 to 14 next year. More than 10,000 people from 500 companies from around the world will participate in this year's event to share pharmaceutical and bio-related information and conduct networking. In addition to global big perm, bio-ventures, government, academia, and investment experts are expected to discuss investment attraction and technology export.

SCM Life Science is ready to focus on cell therapy technology transfer (license out) ahead of the JP Morgan Healthcare Conference. In particular, expectations for technology exports are increasing by sharing the successful research progress of several pipelines.

Previously, on the 16th, the company drew great attention by releasing the interim clinical results of SCM-AGH, a stem cell treatment for atopic dermatitis based on its own stem cells. This is because 68% of all patients administered showed a clear improvement effect in the interim results of phase 1/2 clinical trials, and long-term persistent effects were maintained in all patients who lasted more than 24 weeks.

In addition, earlier this month, the American Society of Hematology (ASH) announced that seven out of nine patients with acute lymphocytic leukemia who received high doses in phase 1/2 of the clinical trial of the homogeneous "CARCIK-CD19" showed complete response (no cancer cells found). The pipeline is a homogeneous CAR-T-based immuno-cancer drug being developed by Coimune, a U.S. joint venture between SCM Life Science and Genexine, and is said to have increased safety by reducing side effects such as cytokine release syndrome, which is considered a limitation of existing auto-CAR-T treatments.

In addition, treatment is much cheaper than the self-contained CAR-T treatment, which is known to be around 400~500 million, it is expected that the cost burden for patients will be reduced.

An official from SCM Life Science said, "In this JP Morgan, we look forward to collaborate with global partners in earnest as it draws and attends clinical data for atopic dermatitis stem cell therapy.”